Tip os
Log ind

“So I called Novo Nordisk and said I wanted to work for them”

Top picks in English:

Gitte Pedersen’s career began in Novo Nordisk and the Danish drug giant led her to the US, where she is now CEO and co-founder of a diagnostics company in Manhattan – a career that is partly formed by a past peopled by engineers and women’s rights activists.


Gitte l pedersen.JPG
Foto: PR
by Stefan Singh Kailay
Offentliggjort 11.06.14 kl. 15:57

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Novo will no longer offer price guidance

POLFOTO_48689923.jpg Top picks in English:

Novo Nordisk will no longer announce the expected price development for its products on the US market.

Darzalex is still the “star of the show” for Genmab

Top picks in English:

Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.

Zealand carries out USD 89m IPO in the US

Top picks in English:

Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.

Bioporto CEO despite growing deficit: ”A fantastic six months”

Top picks in English:

Bioporto’s sales of antibodies and the kidney test NGAL for research use have grown rapidly in 2017. Despite this, the company is forced to downgrade its financial expectations, now expecting a larger deficit for the year. But there is a perfectly good reason for that, explains the CEO.

ALK CEO: We call the FDA on a daily basis

Top picks in English:

Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.

Novo expands its executive team

Top picks in English:

Novo Nordisk has promoted two of its regional directors to its executive management team, which has undergone a slew of changes in the past year.

Forsiden lige nu

Rehabgazelle opruster i Europa

Peter Maindal 5x3.jpg Medico & Rehab:

Det koster på bundlinjen, at den danske virksomhed Vendlet har startet datterselskab i Tyskland, men trods det holder virksomheden fast i sin strategi og åbner endnu en europæisk afdeling.

GN-partner har succes med implantater

Medico & Rehab:

Den australske høreappartsproducent Cochlear vækster på både top- og bundlinje. Godt nyt for danske GN Hearing, der siden 2015 har dannet partnerskab med selskabet.

FDA godkender Pfizer-middel med en advarsel

Medicinal & Biotek:

De amerikanske lægemiddel-myndigheder, FDA, har sagt god for Pfizers nye leukæmimiddel, Besponsa, men godkendelsen inkluderer en alvorlig advarsel.

Demokraterne indleder prisundersøgelse af sklerosemidler

Medicinal & Biotek:

En række større medicinalselskaber mistænkes for uretmæssigt at have hævet priserne på midler til behandling af sklerose. Demokraterne i den amerikanske kongres kræver forklaring.

AstraZeneca og Merck får ny medvind til kræftmiddel

Medicinal & Biotek:

De amerikanske lægemiddel-myndigheder, FDA, har sagt god for en udvidelse af godkendelsen til et middel mod æggestokkekræft udviklet af AstraZeneca.

Finanshuse hæver kursmål for GN efter regnskab

Medico & Rehab:

Torsagens positive regnskab for den danske GN-koncern har fået finanshusene til tasterne og til at hæve kursmålene til selskabets aktie.

ANNONCE
ANNONCE


ANNONCE